(2E)-2-(2,4-dichlorophenyl)-2-hydroxyiminoacetonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2E)-2-(2,4-dichlorophenyl)-2-hydroxyiminoacetonitrile
• 化学式: C₈H₄Cl₂N₂O
• 分子量: 215.03
• InChiKey: XDFJFHBOTSEFLD-WQLSENKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR
  申请人：Uchida Hiroshi

  公开号：US20130079306A1

  公开（公告）日：2013-03-28

  A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

  提供了一种新型杂环化合物或其盐，用于选择性地抑制p27Kip1的降解。该化合物或其盐由以下式（1）表示：其中A代表烷基、环烷基、芳基或杂环基，基团A可能有取代基；环B代表5至8成员的单环杂环环或包含该单环杂环环的缩合环，环B可能有取代基；环C代表芳香环，环C可能有取代基；L代表包含3至5个原子的主链的连接物，所述原子选自碳原子、氮原子、氧原子和硫原子组成的群，其中主链中的至少一个原子是选自氮原子、氧原子和硫原子组成的杂原子，连接物L可能有取代基；n为0或1。
• Neue Oximäther, Verfahren zu ihrer Herstellung, Mittel die die neuen Oximäther enthalten und ihre Verwendung
  申请人：CIBA-GEIGY AG

  公开号：EP0092517A1

  公开（公告）日：1983-10-26

  Oximäther der Formel I in welcher n 1 oder 2, R1 und R2 je Wasserstoff oder C1-C4 Alkyl, R3 und R4 je Wasserstoff, Halogen, C1-C4 Alkyl, C1-C4-Halogenalkyl, C1-C4 Alkoxy, C1-C4 Halogenalkoxy, C1-C4 Alkylthio, C1-C4 Halogenalkylthio, C1-C4 Alkylsulfinyl, C1-C4 Alkylsulfonyl, C1-C4 Halogenalkylsulfinyl, C1-C4 Halogenalkylsulfonyl oder Nitro, R5 und Re einzeln je Wasserstoff, C1-C4 Alkyl, C1-C4 Halogenalkyl, Phenyl, unsubstituiert oder substituiert durch Halogen, CI-C4 Alkyl, C1-C4 Halogenalkyl, C1-C4 Alkoxy, Ci-C4 Halogenalkoxy, C1-C4 Alkylthio, C1-C4 Alkylsulfinyl, C1-C4 Alkylsulfonyl, Carboxyl, Carbamoyl, C1-C4 Alkylcarbamoyl, Nitro oder Cyan, R5 und R6 zusammen auch eine 2-6-gliedrige Alkylen- oder Alkenylenkette, die durch C1-C4 Alkylreste substituiert sein kann, X Wasserstoff, Halogenalkyl, C1-C6 Cycloalkyl, Carboxyl, Carbamoyl, C1-C4 Alkylcarbonyl, C1-C4 Alkoxycarbonyl, C1-C4 Alkylcarbamoyl bedeuten, vermögen als Gegenmittel oder «Safener» Kulturpflanzen vor der phytotoxischen Wirkung von Herbiziden zu schützen. Als Kulturen kommen vorzugsweise Sorghum, Getreide, Mais und Reis in Frage.

  式 I 的肟醚 其中 n 为 1 或 2，R1 和 R2 分别为氢或 C1-C4 烷基，R3 和 R4 分别为氢、卤素、C1-C4 烷基、C1-C4 卤代烷基、C1-C4 烷氧基、C1-C4 卤代烷氧基、C1-C4 烷硫基、C1-C4 卤代烷硫基、C1-C4 烷基亚磺酰基、C1-C4 烷基磺酰基或硝基，R5 和 Re 分别为氢、C1-C4 卤代烷基亚磺酰基、C1-C4 卤代烷基磺酰基或硝基。C1-C4卤代烷基磺酰基、C1-C4卤代烷基磺酰基或硝基，R5 和 Re 各自为氢、C1-C4 烷基、C1-C4 卤代烷基、苯基、未取代或被卤素取代的 CI-C4 烷基、C1-C4 卤代烷基、C1-C4 烷氧基、Ci-C4 卤代烷氧基、C1-C4 卤代烷硫基、C1-C4 卤代烷基硫代烷基、C1-C4 卤代烷基磺酰基、C1-C4 卤代烷基磺酰基或硝基、C1-C4烷硫基、C1-C4烷基亚磺酰基、C1-C4烷基磺酰基、羧基、氨基甲酰基、C1-C4烷基氨基甲酰基、硝基或氰基，R5 和 R6 还可共同形成 2-6 元亚烷基或烯基链，该链可被 C1-C4 烷基、X 氢、卤代烷基、C1-C4 卤代烷基、C1-C4烷基硫基、C1-C4烷基亚磺酰基、C1-C4烷基磺酰基取代、卤代烷基、C1-C6 环烷基、羧基、氨基甲酰基、C1-C4 烷基羰基、C1-C4 烷氧基羰基、C1-C4 烷基氨基甲酰基，它们作为解毒剂或 "安全剂"，能保护作物免受除草剂的植物毒性影响。高粱、谷物、玉米和水稻是最合适的作物。
• Oxim-Derivate zum Schutz von Pflanzenkulturen
  申请人：CIBA-GEIGY AG

  公开号：EP0010143B1

  公开（公告）日：1983-09-28
• HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：EP2594555B1

  公开（公告）日：2018-03-07
• CYANOOXIME INHIBITORS OF CARBONYL REDUCTASE AND METHODS OF USING SAID INHIBITORS IN TREATMENTS INVOLVING ANTHRACYCLINES
  申请人：CHARLIER HENRY A.

  公开号：US20080182804A1

  公开（公告）日：2008-07-31

  Compositions of matter and methods of treating cancer patients are used to prevent or limit cardiotoxicity during or after cancer treatment with anthracycline drugs, and to prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of anthracycline anti-cancer drugs necessary to produce a desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with a pharmaceutical composition comprising compounds having halogenated (or pseudo-halogenated) aryl groups, preferably halogenated (or pseudo-halogenated) arylcyanooximes or phenylcyanooximes and derivatives or analogs thereof, including those comprising —CL or —F, or other substituents on an aryl/phenyl ring. The preferred composition of arylcyanooxime(s) may be administered in a pharmaceutical composition also comprising at least one anthracycline compound, or may be administered separately from the at least one anthracycline compound. Especially-preferred arylcyanooximes include oximino(2,4-difluorophenyl)acetonitrile and/or oximino(2,6-difluorophenyl)acetonitrile and/or oximino(2,5-difluorophenyl)acetonitrile and/or oximino(2-chloro-6-fluorophenyl)acetonitrile and/or oximino(2,4-dichlorophenyl)acetonitrile and/or oximino(2,6-dichlorophenyl)acetonitrile. These six disubstituted halogenated arylcyanooximes may be synthesized using a nitrosation reaction of the respective phenylacetonitriles by neat organic nitrites at room temperature. Most preferably, a high yield of the substituted arylcyanoximes are obtained by nitrosating a substituted phenylacetonitrile by treatment with gaseous methylnitrite, CH 3 ONO, at room temperature or below.